Kevin Bitterman is a Partner at Atlas Venture, which he joined in 2017 after thirteen years on the life science team at Polaris Partners, and focuses on creating and investing in companies that translate science into medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic and Visterra. He currently serves on the boards of Disc Medicine, Judo Bio, Kinaset Therapeutics, nChroma Bio, Remix Therapeutics and Renasant Bio. He holds a Ph.D. in genetics from Harvard Medical School and a B.A. in biology from Rutgers University.
Education
Ph.D. Genetics, Harvard Medical School
B.A. Biology, Rutgers University
Previous Experience
Partner, Polaris Partners (2004-2017)
Founding CEO, Editas Medicine
Founding CEO, Visterra (acquired by Otsuka)
Founding CEO, Morphic Therapeutic (acquired by Eli Lilly)
Notable Investments
Disc Medicine IRONRemix TherapeuticsJudo BioKinaset Therapeutics
Board Seats
Disc Medicine
Judo Bio
Kinaset Therapeutics
nChroma Bio
Remix Therapeutics
Renasant Bio
Career Timeline
2004
Joined the life science team at Polaris Partners.
2017
Joined Atlas Venture as a Partner in June.
2019
Named to the board of Disc Medicine as a founding investor at its 50 million dollar Series A.
2020
Became chair of the board of Remix Therapeutics at its 81 million dollar Series A launch.
2024
Joined the board of Judo Bio at its 100 million dollar launch financing.